close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

NSAIDs: Cancer Prevention for Patients with Barrett's Esophagus

November 11, 2005

NSAIDs: Cancer Prevention for Patients with Barrett's Esophagus

Taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) may help people with Barrett's esophagus from developing throat cancer, according to a new report.

The study, by Dr Thomas L Vaughan and colleagues, was published in The Lancet Oncology online on 7 November and reported by HealthDay.com on 8 November 2005.

Barrett's esophagus is a precancerous condition that primarily affected Caucasian males aged 50 years and older. The condition it characterized by changes in the esophageal lining that make it resemble intestinal tissue. People who have Barrett's esophagus are 50 times more likely to develop esophageal adenocarcinoma, a type of throat cancer that is the most rapidly increasing cancer in the United States, according to HealthDay.com.

"We observed that people who had Barrett's esophagus who were taking aspirin and other NSAIDs were about a third less likely to go on to get esophageal cancer, compared with people who never took NSAIDs regularly," study author Dr. Thomas L. Vaughan, head of the epidemiology program at Fred Hutchinson Cancer Research Center in Seattle, said to HealthDay.com.

The NSAID category of drugs includes aspirin, ibuprofen and naproxen, as well as the COX-2 inhibitors Vioxx, Bextra and Celebrex. Of the COX-2 inhibitors, only Celebrex is still sold in the US, as Vioxx and Bextra have been withdrawn from the US market.

Study Results

Vaughan and colleagues studied data form 350 people diagnosed with Barrett's esophagus. Over a period of more than five years, the researchers examined whether there was a correlation between NSAID use by these patients and development of esophageal adenocarcinoma.

The results showed that people with Barrett's esophagus who took NSAIDs had a 68% lower risk of developing esophageal adenocarcinoma than those who did not use NSAIDs. Moreover, for people who had previously taken NSAIDs, the cancer risk was reduced, although by an insignificant amount.

Among study subjects who had never used NSAIDs, the five-year incidence of esophageal adenocarcinoma was 14.3%; among those who had used NSAIDs regularly in the past it was 9.7%; and among people who currently used NSAIDs it was 6.6%.

"I think this is a pretty exciting finding that gives hope to people with Barrett's," Vaughan said to HealthDay.com. "It gives hope that there may be some prevention, because right now there is no medical or surgical treatment that has been shown to reduce risk in those people."

Implications of the Study

"This is an exciting, well-conducted study," said Eric Jacobs, a senior epidemiologist at the American Cancer Society, to HealthDay.com. "If in the future drugs such as aspirin are proven to substantially reduce progression to cancer for people with Barrett's, it could save lives."

However, Jacobs noted that Vaughan et al's trial was only a small, observational study, saying, "We need evidence from randomized clinical trials before we recommend using NSAIDs for cancer prevention in people with Barrett's."

Jacobs advises two things to help prevent esophageal cancer, according to HealthDay.com: "The first is not to smoke, and if you do smoke, quit. The second is to maintain a good body weight and exercise."

Another medical expert believes the study's findings may be valuable in preventing esophageal cancer.

"Esophageal adenocarcinoma in people with Barrett's esophagus is one of the fastest-growing cancers, and if this finding holds up in a larger population it might be very important," said Dr. Peter Barrett, an assistant professor and medical director of the cardiothoracic surgery intensive care unit at Yale University Medical School, according to HealthDay.com.

"If inexpensive medications such as NSAIDs can help prevent esophageal adenocarcinoma, it is certainly very positive news," Barrett reportedly said. "We do know that NSAID use in colorectal cancer helps prevent precancerous polyps. If this would hold up in the esophagus, it would be important."

However, another doctor noted that taking NSAIDs is not without risks.

"Even as the evidence mounts that aspirin and other NSAIDs may lower your likelihood of certain cancers, the well-documented risks of stomach bleeding requires a discussion with your doctor to determine whether the benefits of using these agents is worth the known risks," said Dr A Mark Fendrick, a professor of internal medicine and health management and policy at the University of Michigan, according to HealthDay.com.

Sources:
Aspirin May Help Prevent Throat Cancer, HealthDay.com/ScoutNews LLC, 8 November 2005.
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study, Thomas L Vaughan et al., Lancet Oncology Early Online Publication, 8 November 2005.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...